- Home
- HOTH
as 12-17-2024 4:00pm EST
Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.
Upcoming Earnings Alert:
Get ready for potential market movements as Hoth Therapeutics Inc. HOTH prepares to release earnings report on 24 Dec 2024.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 5.8M | IPO Year: | 2019 |
| Target Price: | $4.75 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.33 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.58 - $1.73 | Next Earning Date: | 12-24-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Hoth Therapeutics Inc. News
HOTH Breaking Stock News: Dive into HOTH Ticker-Specific Updates for Smart Investing
Barrons.com
a month ago
MicroStrategy Copycats Are Buying Bitcoin as Price Nears $100,000
MT Newswires
a month ago
Hoth Therapeutics Board Approves Purchase of up to $1 Million in Bitcoin; Shares Rise
MT Newswires
a month ago
Hoth Therapeutics Shares Fall After Announcing $2.7 Million At-The-Market Equity Program
MT Newswires
2 months ago
Sector Update: Health Care Stocks Ease Late Afternoon
MT Newswires
2 months ago
Sector Update: Health Care
MT Newswires
2 months ago
Hoth Therapeutics Says Early Data Show HT-KIT Drug Stabilizes Tumor Growth; Shares Jump
PR Newswire
2 months ago
Hoth Therapeutics Announces Update on Cancer Therapeutic HT-KIT Results Suggesting the Treatment Effectively Inhibited Tumor Growth in Preclinical Treatment Study
PR Newswire
2 months ago
Hoth Therapeutics Awarded Key US Patent for Groundbreaking Alzheimer's Treatment and Prepares for Clinical Trials of HT-ALZ with Formulation Now Underway
Compare HOTH vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HOTH Hoth Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.